DOP2014000221A - Métodos para tratar el cáncer usando inhibidor de pi3k e inhibidor de mek - Google Patents

Métodos para tratar el cáncer usando inhibidor de pi3k e inhibidor de mek

Info

Publication number
DOP2014000221A
DOP2014000221A DO2014000221A DO2014000221A DOP2014000221A DO P2014000221 A DOP2014000221 A DO P2014000221A DO 2014000221 A DO2014000221 A DO 2014000221A DO 2014000221 A DO2014000221 A DO 2014000221A DO P2014000221 A DOP2014000221 A DO P2014000221A
Authority
DO
Dominican Republic
Prior art keywords
inhibitor
methods
mek
treat cancer
pi3k
Prior art date
Application number
DO2014000221A
Other languages
English (en)
Inventor
Karl Hsu
Joanne Lager
Janet Anne Meurer Ogden
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of DOP2014000221A publication Critical patent/DOP2014000221A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan métodos de tratamiento de pacientes con cáncer, en donde los métodos comprenden administrar al paciente una cantidad eficaz de un inhibidor de MEK y una cantidad eficaz de un inhibidor de PI3K. Se describen también composiciones en las que se combinan los inhibidores de MEK y PI3K.
DO2014000221A 2012-04-06 2014-10-01 Métodos para tratar el cáncer usando inhibidor de pi3k e inhibidor de mek DOP2014000221A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261621252P 2012-04-06 2012-04-06
FR1351158 2013-02-12
US201361771457P 2013-03-01 2013-03-01

Publications (1)

Publication Number Publication Date
DOP2014000221A true DOP2014000221A (es) 2014-12-15

Family

ID=49301040

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2014000221A DOP2014000221A (es) 2012-04-06 2014-10-01 Métodos para tratar el cáncer usando inhibidor de pi3k e inhibidor de mek

Country Status (18)

Country Link
US (1) US20150031882A1 (es)
EP (1) EP2854854A1 (es)
JP (1) JP2015515476A (es)
KR (1) KR20150003786A (es)
CN (1) CN104334192A (es)
AU (1) AU2013243429A1 (es)
CA (1) CA2869152A1 (es)
CL (1) CL2014002668A1 (es)
CO (1) CO7121349A2 (es)
CR (1) CR20140480A (es)
DO (1) DOP2014000221A (es)
EA (1) EA201491836A1 (es)
MX (1) MX2014012001A (es)
PE (1) PE20142020A1 (es)
PH (1) PH12014502219A1 (es)
SG (1) SG11201406199TA (es)
TN (1) TN2014000418A1 (es)
WO (1) WO2013152165A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2918375T3 (es) 2013-12-20 2022-07-15 Biomed Valley Discoveries Inc Tratamientos contra el cáncer usando combinaciones de inhibidores de la ruta de PI3K/Akt y ERK
US10724071B2 (en) 2015-10-14 2020-07-28 Nitto Boseki Co., Ltd. Method for determining drug-sensitive human cell lines by analysis method in which measurement of activity of two types of protein kinase is used

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1802579T3 (da) 2004-10-20 2014-01-20 Merck Serono Sa Derivater af 3-arylaminopyridin
CN101395155A (zh) * 2005-10-07 2009-03-25 埃克塞里艾克西斯公司 PI3Kα的吡啶并嘧啶酮抑制剂
JP5270353B2 (ja) 2005-10-07 2013-08-21 エクセリクシス， インク． ホスファチジルイノシトール３−キナーゼインヒビターとその使用方法
EP2488178B1 (en) * 2009-10-12 2016-11-16 F.Hoffmann-La Roche Ag Combinations of a pi3k inhibitor and a mek inhibitor
AR084216A1 (es) * 2010-12-09 2013-05-02 Sanofi Sa Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit

Also Published As

Publication number Publication date
CA2869152A1 (en) 2013-10-10
CN104334192A (zh) 2015-02-04
JP2015515476A (ja) 2015-05-28
PE20142020A1 (es) 2014-12-24
TN2014000418A1 (en) 2016-03-30
MX2014012001A (es) 2015-05-11
CR20140480A (es) 2014-11-17
AU2013243429A1 (en) 2014-10-23
KR20150003786A (ko) 2015-01-09
CO7121349A2 (es) 2014-11-20
CL2014002668A1 (es) 2015-01-16
WO2013152165A1 (en) 2013-10-10
SG11201406199TA (en) 2014-10-30
EP2854854A1 (en) 2015-04-08
PH12014502219A1 (en) 2015-01-12
US20150031882A1 (en) 2015-01-29
EA201491836A1 (ru) 2015-02-27

Similar Documents

Publication Publication Date Title
CY1122186T1 (el) Μεθοδοι θεραπειας καρκινου
GT201700167A (es) Terapias de combinación para el tratamiento de cánceres.
ZA202208792B (en) Methods of treating and preventing graft versus host disease
DOP2013000131A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek
GT201300320A (es) Terapia de combinación que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cáncer.
CR20150376A (es) Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos
CL2015002807A1 (es) Terapia de combinación
NI201400111A (es) Tratamiento del cáncer con inhibidores tor cinasa
NI201400109A (es) Tratamiento del cáncer con inhibidores tor cinasa
NI201400110A (es) Tratamiento del cáncer con inhibidores tor cinasa
NI201400112A (es) Tratamiento del cáncer con inhibidores tor cinasa
NI201500055A (es) Tratamiento de cáncer de próstata con inhibidores de quinasa tor
ECSP14013244A (es) COMPOSICIONES Y MÉTODOS PARA TRATAR EL CÁNCER USANDO EL INHIBIDOR DE PI3Kbeta Y EL INHIBIDOR DE LA VÍA DE MAPK, INCLUIDOS LOS INHIBIDORES DE MEK Y RAF
AR102871A1 (es) Métodos de tratamiento de fibrosis
ECSP13012988A (es) Derivados de tienopirimidina (2,3-d) y su uso para tratar arritmia
DOP2014000221A (es) Métodos para tratar el cáncer usando inhibidor de pi3k e inhibidor de mek
UY35033A (es) Formulación en comprimidos de un inhibidor de la fosfatidilinositol 3-cinasa
NI201300052A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek
CO6721062A2 (es) Cmposiciones y métodos para tratar el cancer usando un inhibidor de pi3k y un inhibidor de mek
ECSP13012736A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek
GT201300148A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de p13k y un inhibidor de mek
TN2013000247A1 (en) Compositions comprising a pi3k inhibitor and a mek inhibitor and their use for treating cancer
DOP2017000174A (es) Terapias de combinación para el tratamiento de cánceres
DOP2009000132A (es) Inhibidores de la actividad de la akt